Sara M May1, Martha F Hartz1, Avni Y Joshi1, Miguel A Park2. 1. Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota. 2. Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: may.sara1@mayo.edu.
Abstract
BACKGROUND: Group B Streptococcus (GBS) is the leading infectious cause of neonatal morbidity and mortality in the United States. Intrapartum administration of antibiotics to mothers with positivity to GBS is performed for prevention, with penicillin being the drug of choice. Previous studies have noted an increase in atopic diseases other than drug allergy associated with intrapartum antibiotic exposure. OBJECTIVE: To determine whether intrapartum exposure to penicillin for GBS increases the likelihood of penicillin allergy in children. METHODS: Retrospective chart review was performed for patients from a birth cohort. The birth cohort included children born in 2007 at a tertiary care hospital and had local addresses. Information on GBS status of the mother, intrapartum antibiotic exposure, delivery mode, and birth order was collected and analyzed. RESULTS: Of 927 children identified, 804 were included in the cohort. Eighty children (10%) had a reported penicillin allergy; most were white (79%) and boys (61%). Intrapartum exposure to penicillin (odds ratio 0.84, 95% confidence interval 0.45-1.57, P = .59) or to amoxicillin or ampicillin (odds ratio 0.22, 95% confidence interval 0.01-3.71, P = .29) did not increase the risk of penicillin allergy in children. In addition, all other factors evaluated did not affect the risk of penicillin allergy in children. CONCLUSION: To the authors' knowledge, this is the first study to evaluate intrapartum exposure to penicillin for GBS treatment and subsequent development of penicillin allergy in the child. In contrast to other atopic diseases, intrapartum antibiotic exposure does not alter the risk of penicillin allergy. Parents and obstetricians should be reassured when using penicillin for prevention of neonatal GBS. Published by Elsevier Inc.
BACKGROUND:Group B Streptococcus (GBS) is the leading infectious cause of neonatal morbidity and mortality in the United States. Intrapartum administration of antibiotics to mothers with positivity to GBS is performed for prevention, with penicillin being the drug of choice. Previous studies have noted an increase in atopic diseases other than drug allergy associated with intrapartum antibiotic exposure. OBJECTIVE: To determine whether intrapartum exposure to penicillin for GBS increases the likelihood of penicillinallergy in children. METHODS: Retrospective chart review was performed for patients from a birth cohort. The birth cohort included children born in 2007 at a tertiary care hospital and had local addresses. Information on GBS status of the mother, intrapartum antibiotic exposure, delivery mode, and birth order was collected and analyzed. RESULTS: Of 927 children identified, 804 were included in the cohort. Eighty children (10%) had a reported penicillinallergy; most were white (79%) and boys (61%). Intrapartum exposure to penicillin (odds ratio 0.84, 95% confidence interval 0.45-1.57, P = .59) or to amoxicillin or ampicillin (odds ratio 0.22, 95% confidence interval 0.01-3.71, P = .29) did not increase the risk of penicillinallergy in children. In addition, all other factors evaluated did not affect the risk of penicillinallergy in children. CONCLUSION: To the authors' knowledge, this is the first study to evaluate intrapartum exposure to penicillin for GBS treatment and subsequent development of penicillinallergy in the child. In contrast to other atopic diseases, intrapartum antibiotic exposure does not alter the risk of penicillinallergy. Parents and obstetricians should be reassured when using penicillin for prevention of neonatal GBS. Published by Elsevier Inc.
Authors: Erin K Willits; Miguel A Park; Martha F Hartz; Cathy D Schleck; Amy L Weaver; Avni Y Joshi Journal: Mayo Clin Proc Date: 2018-10 Impact factor: 7.616
Authors: Miren B Dhudasia; Jonathan M Spergel; Karen M Puopolo; Corinna Koebnick; Matthew Bryan; Robert W Grundmeier; Jeffrey S Gerber; Scott A Lorch; William O Quarshie; Theoklis Zaoutis; Sagori Mukhopadhyay Journal: Pediatrics Date: 2021-04-08 Impact factor: 7.124